Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Rating Upgraded by Zacks Investment Research

Eagle Pharmaceuticals (NASDAQ:EGRX) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “

Several other research firms have also recently weighed in on EGRX. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, August 3rd. BidaskClub cut shares of Eagle Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $53.67.

Eagle Pharmaceuticals stock opened at $38.90 on Tuesday. The stock has a market capitalization of $529.31 million, a PE ratio of -117.88 and a beta of 0.77. Eagle Pharmaceuticals has a twelve month low of $33.80 and a twelve month high of $64.94. The company has a quick ratio of 3.97, a current ratio of 4.16 and a debt-to-equity ratio of 0.16. The company has a 50 day moving average of $41.88 and a 200-day moving average of $46.22.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings results on Monday, August 10th. The specialty pharmaceutical company reported $0.57 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.33. The company had revenue of $41.94 million during the quarter, compared to analysts’ expectations of $37.46 million. Eagle Pharmaceuticals had a negative net margin of 2.54% and a positive return on equity of 4.11%. Equities analysts anticipate that Eagle Pharmaceuticals will post -0.41 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in EGRX. Tang Capital Management LLC acquired a new stake in Eagle Pharmaceuticals in the first quarter valued at $11,758,000. Schroder Investment Management Group lifted its stake in Eagle Pharmaceuticals by 412.5% in the first quarter. Schroder Investment Management Group now owns 245,497 shares of the specialty pharmaceutical company’s stock valued at $11,619,000 after acquiring an additional 197,592 shares during the last quarter. Prudential Financial Inc. lifted its stake in Eagle Pharmaceuticals by 82.2% in the second quarter. Prudential Financial Inc. now owns 213,045 shares of the specialty pharmaceutical company’s stock valued at $10,222,000 after acquiring an additional 96,125 shares during the last quarter. Aviva PLC acquired a new stake in Eagle Pharmaceuticals in the first quarter valued at $3,884,000. Finally, Acadian Asset Management LLC lifted its stake in Eagle Pharmaceuticals by 272.9% in the first quarter. Acadian Asset Management LLC now owns 88,013 shares of the specialty pharmaceutical company’s stock valued at $4,049,000 after acquiring an additional 64,413 shares during the last quarter. Hedge funds and other institutional investors own 95.38% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

See Also: Stocks at 52 Week High

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.